$0.87 EPS Expected for Bausch Health Companies Inc. (BHC)

October 13, 2018 - By Adrian Mccoy

Analysts expect Bausch Health Companies Inc. (NYSE:BHC) to report $0.87 EPS on November, 6.They anticipate $0.17 EPS change or 16.35 % from last quarter’s $1.04 EPS. BHC’s profit would be $304.22M giving it 7.09 P/E if the $0.87 EPS is correct. After having $0.93 EPS previously, Bausch Health Companies Inc.’s analysts see -6.45 % EPS growth. The stock increased 2.24% or $0.54 during the last trading session, reaching $24.66. About 4.21 million shares traded. Bausch Health Companies Inc. (NYSE:BHC) has risen 63.13% since October 13, 2017 and is uptrending. It has outperformed by 47.51% the S&P500.

Bausch Health Companies Inc. develops, makes, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company has market cap of $8.62 billion. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal. It currently has negative earnings. The firm also develops and markets products that treat gastrointestinal and hepatologic conditions comprising hepatic encephalopathy, irritable bowel syndrome with diarrhea, traveler's diarrhea, opioid-induced constipation, ulcerative colitis, and others.

More notable recent Bausch Health Companies Inc. (NYSE:BHC) news were published by: Streetinsider.com which released: “Bausch Health Co. Inc. (BHC) Receives Tentative FDA Approval for BRYHALI” on October 08, 2018, also Seekingalpha.com with their article: “Bausch Health’s psoriasis lotion successful in late-state studies” published on October 02, 2018, Bizjournals.com published: “With an assist from Bausch Health, Dova to add 100 sales professionals to market gastro drug” on October 01, 2018. More interesting news about Bausch Health Companies Inc. (NYSE:BHC) were released by: Seekingalpha.com and their article: “Insider Weekends: 3 Insiders Of The Company Formerly Known As Valeant Pharmaceuticals Buy Stock” published on September 25, 2018 as well as Streetinsider.com‘s news article titled: “Bausch Health (BHC) Announces Publication of Phase 3 Efficacy, Safety Data on ALTRENO Lotion, 0.05% in JDD” with publication date: October 11, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.